Additional file 11: Figure S8.
Biomarker subpopulation treatment effect pattern plot (STEPP) analysis of the ADalimumab ACTemrA (ADACTA) trial. Assessment of individual biomarkers compared with treatment effect. One-dimensional STEPP analysis of week-24 American College of Rheumatology (ACR) 50 relative treatment effectiveness of adalimumab compared with tocilizumab for the serum markers soluble intercellular adhesion molecule 1 (sICAM1) (A) and C-X-C motif chemokine 13 (CXCL13) (B) respectively in the ADACTA trial. Week-24 ACR50 odds ratios are shown in solid blue and 95% CIs as accompanying dashed lines. The x-axes correspond to the subgroup of subjects whose baseline biomarker levels were within 20 percentiles below and above the indicated subpopulation median with actual values (pg/ml) in parentheses. The dotted horizontal line indicates equivalent relative treatment effect. (C) Two-dimensional STEPP analysis for sICAM1 and CXCL13. Each cell of the heatmap corresponds to a subgroup of subjects whose baseline biomarker levels were within 25 percentiles below and above the indicated subpopulation median as defined by each biomarker. Concentrations of each biomarker at the indicated percentage are in parentheses in plot margins. Heatmap colors indicate odds ratio (95% CI in brackets) from logistic regression corresponding to outcomes for adalimumab versus tocilizumab. Counts of subjects in each treatment arm for each subgroup are indicated as n = (tocilizumab)/(adalimumab).
Format: ZIP Size: 353KB Download file
Dennis et al. Arthritis Research & Therapy 2014 16:R90 doi:10.1186/ar4555